An oral antihyperglycemic agent, metformin, can affect cell proliferation and antitumor activity in HNSCC through AMPK activation and mTOR inhibition by targeting mitochondrial complex I in HNSCC cells (183). This evidence concerns the gene MTOR and head and neck squamous cell carcinoma.